Dr. Juan R Cubillos-Ruiz
Assistant Professor of Microbiology and Immunology in the Department of Obstetrics and Gynecology , Weill Cornell Medical College, USA
Juan R. Cubillos-Ruiz, Ph.D. is an Assistant Professor of Microbiology and Immunology in the Department of Obstetrics and Gynecology and the Meyer Cancer Center of Weill Cornell Medical College in New York City. Dr. Cubillos-Ruiz completed his Ph.D. in Tumor Immunology at Dartmouth Medical School (Hanover, NH, USA) under the guidance of Dr. Jose Conejo-Garcia, and pursued his postdoctoral training at Harvard University and Weill Cornell Medical College under the mentorship of world-class immunologist Dr. Laurie Glimcher. Dr. Cubillos-Ruiz?s research efforts focus on understanding and targeting the immune microenvironment of lethal gynecological malignancies such as ovarian carcinoma. He has been recipient of competitive awards from the Bill and Melinda Gates Foundation, the Cancer Research Institute, the Ragon Institute of MGH, MIT and Harvard, and the Ovarian Cancer Research Fund. His overarching goal is to devise the next generation of targeted immunotherapies to control and prevent recurrence of aggressive carcinomas.
Research efforts in the Cubillos-Ruiz Lab at Weill Cornell Medical College are aimed at uncovering new therapeutic strategies for harnessing the immune system?s ability to control cancer. Our group combines immunology, cancer biology, genetics, nanotechnology and metabolic profiling to uniquely understand the molecular mechanisms by which tumors paralyze and further manipulate the natural protective function of immune cells. We recently established that lethal cancers induce a state of ?sustained endoplasmic reticulum (ER) stress? in leukocytes as a novel mechanism to cripple protective anti-tumor immunity. Therefore, our dynamic research team is focused on identifying and disabling new mechanisms of immune-suppression orchestrated by abnormal ER stress responses in the tumor microenvironment. We seek to exploit this knowledge for developing the next generation of targeted cancer immunotherapies.